Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury
- PMID: 17610352
- DOI: 10.1089/neu.2006.0216
Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury
Abstract
We previously demonstrated that fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, reduced the neurological deficit, the edema and the cerebral lesion induced by traumatic brain injury (TBI). In order to elucidate these beneficial effects, in the present study, we investigated, in the same TBI model, fenofibrate's effects on the inflammation and oxidative stress. Male Sprague Dawley rats were randomized in four groups: non-operated, sham-operated, TBI + vehicle, TBI + fenofibrate. TBI was induced by lateral fluid percussion of the temporoparietal cortex. Rats were given fenofibrate (50 mg/kg) or its vehicle (water containing 0.2% methylcellulose), p.o. 1 and 6 h after brain injury. A neurological assessment was done 24 h after TBI, then rats were killed and the brain COX2, MMP9 expression, GSx, GSSG levels were determined. The same schedule of treatment was used to evaluate the effect of fenofibrate on immunohistochemistry of 3NT, 4HNE and iNOS at 24 h post-injury. Our results showed that fenofibrate promotes neurological recovery by exerting anti-inflammatory effect evidenced by a decrease in iNOS, COX2 and MMP9 expression. In addition, fenofibrate showed anti-oxidant effect demonstrated by a reduction of markers of oxidative stress: loss of glutathione, glutathione oxidation ratio, 3NT and 4HNE staining. Our data suggest that PPARalpha activation could mediate pleiotropic effects and strengthen that it could be a promising therapeutic strategy for TBI.
Similar articles
-
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury.Neurosci Lett. 2005 Nov 4;388(1):7-12. doi: 10.1016/j.neulet.2005.06.019. Neurosci Lett. 2005. PMID: 16087294
-
Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.J Pharmacol Exp Ther. 2008 Sep;326(3):966-74. doi: 10.1124/jpet.108.140368. Epub 2008 Jun 18. J Pharmacol Exp Ther. 2008. PMID: 18562561
-
Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.Eur J Pharmacol. 2012 Jan 5;674(1):33-43. doi: 10.1016/j.ejphar.2011.10.029. Epub 2011 Oct 26. Eur J Pharmacol. 2012. PMID: 22056833
-
Fenofibrate: metabolic and pleiotropic effects.Curr Vasc Pharmacol. 2005 Jan;3(1):87-98. doi: 10.2174/1570161052773942. Curr Vasc Pharmacol. 2005. PMID: 15638786 Review.
-
Protective role of peroxisome proliferator-activated receptor α agonists in skin barrier and inflammation.Immunobiology. 2018 Mar;223(3):327-330. doi: 10.1016/j.imbio.2017.10.047. Epub 2017 Oct 27. Immunobiology. 2018. PMID: 29111315 Review.
Cited by
-
Suppressor of Cytokine Signaling-2 (SOCS2) Regulates the Microglial Response and Improves Functional Outcome after Traumatic Brain Injury in Mice.PLoS One. 2016 Apr 12;11(4):e0153418. doi: 10.1371/journal.pone.0153418. eCollection 2016. PLoS One. 2016. PMID: 27071013 Free PMC article.
-
Pharmacology of traumatic brain injury: where is the "golden bullet"?Mol Med. 2008 Nov-Dec;14(11-12):731-40. doi: 10.2119/2008-00050.Beauchamp. Epub 2008 Aug 18. Mol Med. 2008. PMID: 18769636 Free PMC article. Review.
-
Profiling sensory neuron microenvironment after peripheral and central axon injury reveals key pathways for neural repair.Elife. 2021 Sep 29;10:e68457. doi: 10.7554/eLife.68457. Elife. 2021. PMID: 34586065 Free PMC article.
-
Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy.Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):483-98. doi: 10.1007/s10096-010-1122-9. Epub 2010 Dec 9. Eur J Clin Microbiol Infect Dis. 2011. PMID: 21140187 Review.
-
Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review.J Ophthalmol. 2018 Jan 17;2018:1694187. doi: 10.1155/2018/1694187. eCollection 2018. J Ophthalmol. 2018. PMID: 29576875 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous